OpenLegislation

The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017

S.I. 2017/632 · Made 6 May 2017

Original text. legislation.gov.uk does not revise statutory instruments, so later amendments are not shown here. Changes made to it are listed under each provision when known.

Dangerous Drugs, England And Wales

Dangerous Drugs, Scotland

Made 6th May 2017

Coming into force 31st May 2017

To be laid before Parliament 13th June 2017

The Secretary of State, in exercise of the powers conferred by sections 7(4) and 7(5) of the Misuse of Drugs Act 1971f1, and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 7(7) of that Act, makes the following Order:

Annotations to the whole text

Footnotes

f1

1971 c. 38.

Contents

  1. 1Citation, commencement and extent
  2. 2Amendment to the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015
  3. Signature
  4. Explanatory note

1Citation, commencement and extent

(1)

This Order may be cited as the Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 and comes into force on 31st May 2017.

(2)

This Order extends to England and Wales and Scotland.

2Amendment to the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015

(1)

The Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015f1 is amended as follows.

(2)

In paragraph 1(a) of Part 1 of the Schedule—

(a)

before “Bufotenine” insert—

  • “Adinazolam (1-(8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine)

  • N-Benzyl-ethylphenidate

  • Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)”;

(b)

after “Cathinone” insert—

  • “4’-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

  • Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)”;

(c)

after “Concentrate of poppy-straw” insert—

  • “Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)

  • 3,4-Dichloroethylphenidate

  • 3,4-Dichloromethylphenidate (3,4-DCMP)

  • Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

  • Ethylnaphthidate

  • Ethylphenidate”;

(d)

after “Eticyclidine” insert—

  • “Etizolam”;

(e)

after “Etryptamine” insert—

  • “Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

  • Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)

  • 4-Fluoroethylphenidate

  • 4-Fluoromethylphenidate

  • Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;

(f)

after “Gamma-butyrolactone” insert—

  • “3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

  • Isopropylphenidate (IPP or IPPD)”;

(g)

after “Lysergide and other N-alkyl derivatives of lysergamide” insert—

  • “Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;

(h)

after “Methcathinone” insert—

  • “4-Methylmethylphenidate

  • Methylmorphenate

  • Methylnaphthidate (HDMP-28)

  • Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)

  • Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2- one)

  • Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)

  • Propylphenidate”;

(i)

after “Psilocin” insert—

  • “Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)”;

(j)

after “3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)” insert—

  • “3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47,700)”.

Signature

Sarah Newton

Parliamentary Under Secretary of State

Home Office

6th May 2017

Explanatory note

(This note is not part of the Order)

Section 7(3) of the Misuse of Drugs Act 1971 requires regulations to be made to allow the use for medical purposes of the drugs which are subject to control under that Act. Section 7(3) does not apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order amends the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 (S.I. 2015/704) by inserting a synthetic opioid (U-47,700), several methylphenidate related materials and a number of designer benzodiazepines into Part 1 of the Schedule to that Order.

An impact assessment will be published alongside the Explanatory Memorandum on the legislation.gov.uk website.